Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
LONDON, March 22, 2016 -- APCER Life Sciences, the truly global provider of safety, medical, regulatory, and technology services, will be a major participant in the Drug Information Association’s 28th Annual EuroMeeting, taking place April 6-8, 2016, in Hamburg, Germany. The company will host a presentation in the Innovation Theatre and have a large presence in the exhibit hall of the Congress Center Hamburg.
“We are excited that we have reached the point in our company’s growth where we can support the DIA EuroMeeting at a significant level,” said Michael Britt, APCER Europe’s business unit leader and Global Head of Quality and Compliance. “The European clients that we have been serving since our founding helped us define our value proposition and build our firm into the global presence it is today.”
APCER’s presentation in the Innovation Theatre is titled “Redefining PV: From Pharmacovigilance to Patient Voice and Product Value.” It will explore how pharmacovigilance, when practiced with consistency and integrated tightly with medical affairs, can yield a rich source of real-world patient data that quantifies product value and demonstrates a competitive advantage for partnering and out-licensing deals, formulary decisions, and reimbursement rates.
APCER Life Sciences is active in the Drug Information Association around the world. In addition to the EuroMeeting, the company will be speaking at the DIA Innovations in Pharmacovigilance meeting in Mumbai, India, May 13-14, and at the 52nd DIA Annual Meeting in Philadelphia, Pennsylvania, USA, June 27-30. APCER is also exhibiting at the DIA Medical Affairs and Scientific Communications Annual Forum in Orlando, Florida, USA, this week.
About APCER Life Sciences
APCER Life Sciences is committed to improving health in partnership with its clients. It brings together safety, medical, regulatory, and technology resources from around the world to ensure that patients receive the safest, most effective therapies possible.
To learn how APCER Life Sciences works together for better health, please follow the company on Twitter, LinkedIn, and Facebook; visit www.apcerls.com; then contact APCER at one of their global offices.
Contact: Jill Notte Director, Global Marketing +1-609-436-4714
